Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. The Company’s mission is to introduce much needed innovations to infectious disease treatment using an anti-infective product portfolio that includes four (4) clinical stage and two preclinical drug candidates. Our antimicrobial product candidates are highly differentiated from conventional antibiotics in mechanisms of action, and are being developed using clinical study designs that allow for clear demonstration of superiority over standard of care antibiotics.
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation.
A core focus of our innovation is the discovery and development of monoclonal antibodies from convalescent infected patients. Monoclonal antibodies (mAbs) are proteins produced by our ‘humoral’ immune system to neutralize the pathogens in a targeted fashion. Monoclonal antibodies exert their actions in multiple ways, all of which are largely distinct from antibiotics or antivirals, e.g. mAbs bind to the pathogen’s surface to block key functions, block entry into host cells, neutralize toxins, or to improve recognition by other immune cells.
Our products target infectious diseases that have a significant impact on life expectancy and address acute medical needs including:
AR-301 (SalvecinTM) is a fully human monoclonal IgG1 antibody that specifically targets S. aureus alpha-toxin, a toxic protein secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA). AR-301 protects against alpha-toxin dependent destruction, preserving the human immune cells.
AR-501 is a novel small molecule anti-infective that diversifies our mAb immunotherapy-focused product portfolio. AR-501 is an inhalable form of gallium citrate, which acts as an iron analog to starve bacteria of iron. Gallium is believed to inhibit multiple iron-dependent synthetic and metabolic pathways required for pathogenicity. As with our monoclonal antibody programs, the mechanism of action of AR-501 is different from all antibiotics, and is effective against antibiotic resistant bacteria.
AR-101 (AerumabTM) is a highly specific monoclonal antibody targeted against P. aeruginosa lipopolysaccharide serotype O11, which accounts for ~22% of all P. aeruginosa hospital-acquired infections worldwide. Binding of AR-101 to P. aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human phagocytes.
AR-701 is a cocktail of mAbs directed against the envelope proteins on the SARS-CoV-2 virus (COVID-19). It discovered from screening the immune system of convalescent COVID-19 patients and is designed to broadly inhibit COVID-19 variants and exhibits prolonged plasma half-life to extend the durability of protection beyond conventional mAbs.
Complementing our current clinical pipeline, we have two additional drug candidates in preclinical development. AR-201 is a human IgG1 mAb directed against the F-protein of respiratory syncytial virus (RSV). AR-401 is a mAb discovery program to treat infections caused by the Gram-negative bacterium Acinetobacter baumannii.
In virtually all infectious diseases, there is a subset of disease-free individuals that may be generating rare, potent, protective immune responses to even the most lethal pathogens. Human monoclonal antibodies are often the key protective components. Our discovery technology platform aims to find and transform these components into innovative therapies to treat the masses.